Andrey Pinchuk

Many microbial products show strong early efficacy using lab prepared microbial material that may not reflect the final commercial product. This roundtable will explore how developers can reduce commercialization risk by aligning field validation with commercial realities earlier, including target markets, product claims, formulation design, fermentation and formulation scale-up, shelf stability, quality control, application fit, regulatory requirements, manufacturing reliability, and the COGS needed for market adoption.

• What risks are created when field testing is built around microbial material that is not commercially representative?
• How do programs break down when shelf life, application fit, quality control, manufacturing consistency, regulatory requirements, and COGS are addressed only after efficacy is established?
• What should companies prove before full commercial scale-up, and how can earlier commercially representative formulations support better field data, regulatory planning, and commercialization decisions?